GET DAILY SIGNALSCandel Therapeutics (CADL) Reports Wider Q3 Loss as BLA Submission Moves to Mid-2027
Key Takeaways
- Candel Therapeutics reported a third quarter 2026 net loss of approximately $21.9 million, widening from $11.3 million in the prior-year period.
- Net loss per share came in at $0.28, narrower than consensus estimates that had ranged from roughly $0.30 to $0.34 per share.
- The company pushed back its planned Biologics License Application (BLA) submission for aglatimagene in localized prostate cancer to mid-2027, from a prior fourth quarter 2026 target.
- Rising research and development (R&D) spending drove the year-over-year widening of the loss as the company advanced its clinical-stage pipeline.
- Candel remains in ongoing dialogue with the U.S. Food and Drug Administration (FDA) regarding the aglatimagene submission timeline.
Why This Quarter Matters for CADL
Candel Therapeutics (CADL) is a clinical-stage biopharmaceutical company focused on oncolytic viral immunotherapies that aim to convert "cold" tumors into "hot" ones more visible to the immune system. With no approved products on the market, the company has no meaningful product revenue, so quarterly updates tend to center on two key areas: the rate of spending on its pipeline and the advancement of its lead candidate, aglatimagene, toward a regulatory filing. The third-quarter results speak directly to both. A larger net loss signals increased R&D investment, while the revised timeline for the aglatimagene BLA filing carries real implications for how the market values the stock.
Quarterly Results in Detail
Candel reported a third quarter 2026 net loss of about $21.9 million, compared with $11.3 million in the same period last year. The increase stemmed primarily from higher R&D expenses linked to clinical and manufacturing work on its viral immunotherapy programs. On a per-share basis, the company recorded a basic and diluted net loss of $0.28, versus $0.21 a year earlier. The reported loss per share came in better than Wall Street consensus estimates, which had ranged from roughly $0.30 to $0.34 per share ahead of the release.
Given that Candel is still pre-revenue, attention quickly shifted to the regulatory update. Management noted that refinements to certain assays pushed the planned BLA submission for aglatimagene in localized prostate cancer to mid-2027 instead of the fourth quarter of 2026. The company continues to engage actively with the FDA on the filing.
Market Reaction and What Investors Are Watching
Investor sentiment around CADL has long been driven more by regulatory milestones than by quarterly earnings, given the lack of product sales. The delay in the aglatimagene BLA submission to mid-2027 is expected to temper near-term expectations, as that filing had represented the closest potential path to a first approval. At the same time, the narrower-than-forecast loss per share and ongoing FDA dialogue offer some offset. Historically, the stock has seen sharp moves after earnings in either direction, and elevated short interest can magnify volatility around major updates. Investors will likely balance the financing runway and pipeline progress against the extended wait for a commercial catalyst. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Looking Ahead: Key Items to Follow
The most critical development to monitor remains the aglatimagene BLA submission and any additional details on the assay refinements that shifted the timeline into mid-2027. Because the company is in active discussions with the FDA, further updates on the filing’s design and scope could influence expectations well before the formal submission.
Cost control and liquidity will stay important. Candel has previously stated that its cash position should support operations well into 2028, backed by recent equity and royalty-based financing. It will be worth watching whether the higher R&D outlays remain within that runway or if further capital raises are needed.
Additional pipeline updates, including progress on other viral immunotherapy programs, and any signals on manufacturing readiness ahead of a possible launch will also matter. Until a regulatory decision arrives, clinical execution, spending discipline, and milestone timing are likely to shape the stock’s valuation.
Using AI Tools in My Research
When evaluating clinical-stage names like CADL, I find it helpful to run quick scans with Tickeron’s AI Screener to compare technical patterns and fundamentals across the sector. It lets me filter on customizable criteria such as market cap, volatility, and performance metrics, which helps surface relevant ideas more efficiently than manual reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CADL's RSI Oscillator recovers from oversold territory
The RSI Oscillator for CADL moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 26 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CADL as a result. In 91 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for CADL just turned positive on October 28, 2026. Looking at past instances where CADL's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +18.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CADL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CADL entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.308) is normal, around the industry mean (3.498). P/E Ratio (-5.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement